KYAN Therapeutics utilizes its Optim.AI™ ex vivo analytic platform to perform functional precision medicine tests that evaluate drug response using patient-derived cancer cells. This approach addresses the limitations of standard therapies by providing personalized treatment regimens based on the unique sensitivities of each patient's cancer, thereby improving treatment efficacy.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CSFounders
Product
Problem
Cancer treatment is often based on standard therapies that may not be effective for all patients, leading to multiple lines of treatment and potential failures. Identifying effective drug combinations for individual patients is challenging due to the vast number of possible regimens. Traditional precision medicine approaches that rely on biomarker matching may only benefit a small percentage of patients.
Solution
KYAN Therapeutics offers Optim.AI™, an ex vivo analytic platform that performs functional precision medicine tests using patient-derived cancer cells to evaluate drug response. The platform analyzes a vast number of drug regimens to identify the most effective treatment options for each patient's unique cancer. Optim.AI™ empowers oncologists to tailor patient-specific treatments based on personalized results, maximizing the chances of finding an effective treatment. The platform's small data AI efficiently solves large and dynamic complex systems through a minimum number of tests, identifying optimal phenotypic response surfaces across different biological models.
Target Audience
The primary target audience includes oncologists seeking personalized treatment guidance for their patients, as well as biopharmaceutical companies looking to accelerate drug development.
Features
- Ex vivo drug response analysis using patient-derived cancer cells
- Small Data AI to efficiently solve large and dynamic complex systems
- Identification of optimal drug-dose combination therapies
- Evaluation of a vast number of regimens to maximize finding effective treatment
- Ranking of actionable treatments based on sensitivity, including comparisons against standard care
- Clinical decision support for oncologists to guide treatment with personalized results
- Biopharma services for new target prioritization, combination discovery, biomarker identification, dose optimization, and reviving failed assets